Ocuphire Pharma, Inc.

Restoring Vision and Clarity

Ocuphire Pharma is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.

SEE WHO WE ARE

CORPORATE PRESENTATION

A Clear-sighted Product Pipeline

Nyxol®

Targets: Pharmacologically-induced Mydriasis, Presbyopia, and Dim Light or Night Vision Disturbances

Nyxol® Eye Drops is a once-daily preservative-free eye drop formulation designed to reduce pupil size and improve visual acuity.

View Nyxol

APX3330

Targets: Diabetic Retinopathy and Diabetic Macular Edema

APX3330 is a twice-a-day oral tablet, designed to inhibit angiogenesis and inflammatory pathways relevant to retinal and choroidal vascular diseases.

View APX3330

Our Clinical Trials

Ocuphire Pharma plans to readout 4 clinical trials with a potential NDA filing for the RM indication in 2022.

View Clinical Trials

Latest News

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting

View Release

Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

View Release

Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update

View Release

Stock Snapshot

View Investor Relations